Adaptin Bio (APTN) Cash from Operations (2023 - 2026)

Adaptin Bio has disclosed Cash from Operations across 4 years of filings, most recently posting 596298.0 for Q1 2026.

• Quarterly Cash from Operations rose 73.85% year-over-year to 596298.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3094314.0 (down 8.98% YoY) and the FY2025 annual result came in at 4777892.0, down 635.87% from the prior year.
• Cash from Operations advanced to 596298.0 in Q1 2026, from 702876.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 112653.0 in Q4 2024 and bottomed at 2279876.0 in Q1 2025.
• The 4-year median for Cash from Operations is 532357.0 (2024), against an average of 608182.0.
• Year-over-year, Cash from Operations jumped 293.07% in 2024 and plunged 2441.81% in 2025.
• Adaptin Bio's Cash from Operations stood at 58347.0 in 2023, then jumped by 293.07% to 112653.0 in 2024, then tumbled by 723.93% to 702876.0 in 2025, then rose by 15.16% to 596298.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 596298.0, 702876.0, and 772430.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.